دورية أكاديمية
أعرض في EDS

Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype.

التفاصيل البيبلوغرافية
العنوان: Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype.
المؤلفون: Hiltbrunner S; Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, 8091, Switzerland.; Comprehensive Cancer Center Zurich, University Hospital Zurich, Zurich, 8091, Switzerland.; University of Zurich, Zurich, Switzerland.; University of Fribourg, Faculty of Science and Medicine, Fribourg, 1700, Switzerland., Cords L; University of Zurich, Zurich, Switzerland.; Department of Quantitative Biomedicine, University of Zurich, Zurich, 8057, Switzerland.; Institute of Molecular Health Sciences, ETH Zurich, Zurich, 8049, Switzerland.; Life Science Zurich Graduate School, ETH Zurich and University of Zurich, Zurich, Switzerland., Kasser S; Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, 8091, Switzerland.; University of Zurich, Zurich, Switzerland., Freiberger SN; Department of Pathology and Molecular Pathology, University Hospital Zurich, 8091, Zurich, Switzerland., Kreutzer S; Functional Genomics Center Zurich, ETH and University of Zurich, Zurich, 8057, Switzerland., Toussaint NC; NEXUS Personalized Health Technologies, ETH Zurich, Zurich, 8952, Switzerland.; SIB Swiss Institute of Bioinformatics, Lausanne, 1015, Switzerland., Grob L; NEXUS Personalized Health Technologies, ETH Zurich, Zurich, 8952, Switzerland.; SIB Swiss Institute of Bioinformatics, Lausanne, 1015, Switzerland., Opitz I; Department of Thoracic Surgery, University Hospital Zurich, Zurich, 8091, Switzerland., Messerli M; University of Zurich, Zurich, Switzerland.; Department of Nuclear Medicine, University Hospital Zurich, Zurich, 8091, Switzerland., Zoche M; Department of Pathology and Molecular Pathology, University Hospital Zurich, 8091, Zurich, Switzerland., Soltermann A; Department of Pathology and Molecular Pathology, University Hospital Zurich, 8091, Zurich, Switzerland.; Pathologie Länggasse, Ittigen, 3063, Switzerland., Rechsteiner M; Department of Pathology and Molecular Pathology, University Hospital Zurich, 8091, Zurich, Switzerland., van den Broek M; University of Zurich, Zurich, Switzerland.; Institute of Experimental Immunology, University of Zurich, Zurich, 8057, Switzerland., Bodenmiller B; University of Zurich, Zurich, Switzerland.; Department of Quantitative Biomedicine, University of Zurich, Zurich, 8057, Switzerland.; Institute of Molecular Health Sciences, ETH Zurich, Zurich, 8049, Switzerland., Curioni-Fontecedro A; Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, 8091, Switzerland. alessandra.curioni-fontecedro@h-fr.ch.; Comprehensive Cancer Center Zurich, University Hospital Zurich, Zurich, 8091, Switzerland. alessandra.curioni-fontecedro@h-fr.ch.; University of Zurich, Zurich, Switzerland. alessandra.curioni-fontecedro@h-fr.ch.; University of Fribourg, Faculty of Science and Medicine, Fribourg, 1700, Switzerland. alessandra.curioni-fontecedro@h-fr.ch.; Clinic of Oncology, Cantonal Hospital Fribourg, Fribourg, 1752, Switzerland. alessandra.curioni-fontecedro@h-fr.ch.
المصدر: Nature communications [Nat Commun] 2023 Aug 24; Vol. 14 (1), pp. 5154. Date of Electronic Publication: 2023 Aug 24.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : Nature Pub. Group
مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics, Humans ; CD8-Positive T-Lymphocytes ; B7-H1 Antigen/genetics ; Immune Checkpoint Inhibitors ; Immunosuppressive Agents ; Phenotype
مستخلص: Immune checkpoint inhibitor treatment has the potential to prolong survival in non-small cell lung cancer (NSCLC), however, some of the patients develop resistance following initial response. Here, we analyze the immune phenotype of matching tumor samples from a cohort of NSCLC patients showing good initial response to immune checkpoint inhibitors, followed by acquired resistance at later time points. By using imaging mass cytometry and whole exome and RNA sequencing, we detect two patterns of resistance¨: One group of patients is characterized by reduced numbers of tumor-infiltrating CD8 +  T cells and reduced expression of PD-L1 after development of resistance, whereas the other group shows high CD8 +  T cell infiltration and high expression of PD-L1 in addition to markedly elevated expression of other immune-inhibitory molecules. In two cases, we detect downregulation of type I and II IFN pathways following progression to resistance, which could lead to an impaired anti-tumor immune response. This study thus captures the development of immune checkpoint inhibitor resistance as it progresses and deepens our mechanistic understanding of immunotherapy response in NSCLC.
(© 2023. Springer Nature Limited.)
References: Br J Cancer. 2011 Oct 25;105(9):1379-87. (PMID: 21979422)
Nat Genet. 2016 Nov;48(11):1327-1329. (PMID: 27668655)
Front Immunol. 2021 Dec 09;12:773570. (PMID: 34956201)
Jpn J Cancer Res. 1996 Oct;87(10):1063-9. (PMID: 8957065)
Cell. 2017 Feb 9;168(4):707-723. (PMID: 28187290)
Nature. 2020 Feb;578(7796):615-620. (PMID: 31959985)
Nature. 2006 Feb 9;439(7077):682-7. (PMID: 16382236)
Bioinformatics. 2009 Jul 15;25(14):1754-60. (PMID: 19451168)
Nature. 2014 Nov 27;515(7528):577-81. (PMID: 25428507)
PLoS One. 2014 Mar 05;9(3):e90459. (PMID: 24599305)
Cancer Discov. 2017 Dec;7(12):1420-1435. (PMID: 29025772)
Lancet Oncol. 2019 Oct;20(10):1395-1408. (PMID: 31422028)
Trends Immunol. 2017 Aug;38(8):542-557. (PMID: 28579323)
Cancer Discov. 2018 Jul;8(7):822-835. (PMID: 29773717)
Nat Immunol. 2015 Sep;16(9):991-9. (PMID: 26214740)
Nat Commun. 2013;4:2531. (PMID: 24100690)
Cell. 2018 Nov 1;175(4):998-1013.e20. (PMID: 30388456)
J Thorac Oncol. 2010 Oct;5(10):1507-15. (PMID: 20802348)
N Engl J Med. 2012 Jun 28;366(26):2455-65. (PMID: 22658128)
Br J Cancer. 2020 Aug;123(3):392-402. (PMID: 32433601)
Sci Adv. 2019 Feb 20;5(2):eaav2437. (PMID: 30801016)
Cell Rep. 2015 Sep 29;12(12):2099-110. (PMID: 26365183)
Nat Rev Cancer. 2016 Mar;16(3):131-44. (PMID: 26911188)
Nat Immunol. 2019 Mar;20(3):326-336. (PMID: 30778252)
Nucleic Acids Res. 2016 Jul 27;44(13):6274-86. (PMID: 27260798)
Nat Biotechnol. 2013 Mar;31(3):213-9. (PMID: 23396013)
Physiol Rev. 2008 Jul;88(3):841-86. (PMID: 18626062)
Cell Metab. 2019 Mar 5;29(3):755-768.e5. (PMID: 30713109)
Adv Cancer Res. 2008;101:249-76. (PMID: 19055946)
Nat Commun. 2020 Sep 9;11(1):4520. (PMID: 32908154)
BMC Bioinformatics. 2016 May 10;17:208. (PMID: 27161244)
Cancer Discov. 2016 Feb;6(2):147-153. (PMID: 26644315)
Cancer Res. 1988 Oct 15;48(20):5818-24. (PMID: 3139284)
J Thorac Oncol. 2020 May;15(5):777-791. (PMID: 32068166)
Nature. 2014 Jul 31;511(7511):543-50. (PMID: 25079552)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
Cell. 2022 Mar 31;185(7):1189-1207.e25. (PMID: 35325594)
Blood. 2009 Aug 20;114(8):1537-44. (PMID: 19423728)
Cancer Immunol Res. 2015 Dec;3(12):1344-55. (PMID: 26253731)
Cancer Res. 2009 Feb 15;69(4):1517-26. (PMID: 19208838)
Clin Cancer Res. 2014 Oct 1;20(19):5064-74. (PMID: 24714771)
Int J Cancer. 2009 Jan 15;124(2):352-7. (PMID: 18942708)
Nat Rev Immunol. 2006 Nov;6(11):836-48. (PMID: 17063185)
BMC Med. 2006 Dec 26;4(1):38. (PMID: 17190588)
N Engl J Med. 2020 Sep 3;383(10):944-957. (PMID: 32877583)
J Clin Invest. 2015 May;125(5):2046-58. (PMID: 25866972)
Cell. 2016 Mar 24;165(1):35-44. (PMID: 26997480)
Immunity. 2019 Jan 15;50(1):195-211.e10. (PMID: 30635237)
Nature. 2017 Aug 31;548(7669):537-542. (PMID: 28783722)
Oncogene. 2022 Apr;41(18):2571-2586. (PMID: 35322197)
J Clin Oncol. 2015 Jun 20;33(18):2004-12. (PMID: 25897158)
Immunity. 2019 Jan 15;50(1):181-194.e6. (PMID: 30635236)
J Immunother. 2010 Oct;33(8):769-79. (PMID: 20842060)
Nat Commun. 2021 May 5;12(1):2540. (PMID: 33953163)
Nat Rev Immunol. 2015 Jul;15(7):405-14. (PMID: 26027717)
Sci Rep. 2017 Dec 4;7(1):16878. (PMID: 29203879)
Nature. 2014 Nov 27;515(7528):563-7. (PMID: 25428504)
Cell Rep Med. 2022 Mar 15;3(3):100554. (PMID: 35492873)
Cell Immunol. 2017 Mar;313:43-51. (PMID: 28110884)
N Engl J Med. 2015 May 21;372(21):2018-28. (PMID: 25891174)
Biochem Biophys Res Commun. 2010 Mar 19;393(4):829-35. (PMID: 20171165)
J Clin Invest. 2012 Mar;122(3):899-910. (PMID: 22293174)
Nature. 2006 Sep 21;443(7109):350-4. (PMID: 16921384)
Nature. 2017 Jul 27;547(7664):413-418. (PMID: 28723893)
N Engl J Med. 2015 Oct 22;373(17):1627-39. (PMID: 26412456)
J Immunother Cancer. 2019 Mar 12;7(1):68. (PMID: 30867051)
N Engl J Med. 2015 May 21;372(21):2006-17. (PMID: 25891304)
Nat Med. 2017 May;23(5):551-555. (PMID: 28346412)
J Exp Med. 2010 Sep 27;207(10):2175-86. (PMID: 20819923)
J Clin Invest. 2015 Nov 2;125(11):4053-62. (PMID: 26413872)
Nature. 2009 Oct 8;461(7265):788-92. (PMID: 19776740)
Clin Cancer Res. 2013 Jan 15;19(2):393-403. (PMID: 23204132)
PLoS One. 2019 May 24;14(5):e0216864. (PMID: 31125352)
Cancer Discov. 2021 Nov;11(11):2726-2737. (PMID: 34099454)
Nat Genet. 2017 Mar;49(3):349-357. (PMID: 28135248)
Nat Commun. 2018 Sep 24;9(1):3868. (PMID: 30250229)
J Immunol. 2012 Jul 15;189(2):558-66. (PMID: 22685313)
Lancet Oncol. 2017 Mar;18(3):e143-e152. (PMID: 28271869)
Nat Rev Immunol. 2015 Aug;15(8):486-99. (PMID: 26205583)
N Engl J Med. 2015 Jul 2;373(1):23-34. (PMID: 26027431)
Clin Cancer Res. 2014 Dec 15;20(24):6593-604. (PMID: 25294904)
BMC Bioinformatics. 2013 Jan 16;14:7. (PMID: 23323831)
Oncoimmunology. 2021 Jul 21;10(1):1914954. (PMID: 34350059)
Cancer Metastasis Rev. 2003 Dec;22(4):309-25. (PMID: 12884908)
Science. 2009 Nov 27;326(5957):1216-9. (PMID: 19965464)
NPJ Genom Med. 2017;2:. (PMID: 28819565)
J Hematol Oncol. 2020 Jun 29;13(1):83. (PMID: 32600443)
Cancer Res. 2019 Apr 1;79(7):1493-1506. (PMID: 30679180)
Transl Oncol. 2018 Jun;11(3):575-584. (PMID: 29547756)
Nat Commun. 2016 Feb 17;7:10501. (PMID: 26883990)
Cell. 2019 May 16;177(5):1330-1345.e18. (PMID: 30982598)
Nature. 2017 Jan 18;541(7637):321-330. (PMID: 28102259)
Genes Chromosomes Cancer. 2004 Jun;40(2):146-51. (PMID: 15101048)
Nature. 2014 Nov 27;515(7528):558-62. (PMID: 25428503)
Cancer Discov. 2018 Sep;8(9):1156-1175. (PMID: 30012853)
Immunol Rev. 2011 Nov;244(1):197-217. (PMID: 22017440)
Genome Res. 2012 Mar;22(3):568-76. (PMID: 22300766)
Nat Commun. 2018 Nov 8;9(1):4692. (PMID: 30410077)
Bioinformatics. 2018 Jan 1;34(1):107-108. (PMID: 28968639)
Cancer Cell. 2022 Jun 13;40(6):674-693.e7. (PMID: 35594863)
Sci Transl Med. 2013 Aug 28;5(200):200ra116. (PMID: 23986400)
J Exp Med. 2010 Sep 27;207(10):2187-94. (PMID: 20819927)
CA Cancer J Clin. 2017 Jan;67(1):7-30. (PMID: 28055103)
JTO Clin Res Rep. 2021 Dec 04;3(1):100262. (PMID: 35005654)
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1128-35. (PMID: 21093169)
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80. (PMID: 20385810)
Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):E7786-E7794. (PMID: 30061414)
Bioinformatics. 2012 Jul 15;28(14):1811-7. (PMID: 22581179)
Mol Cancer Ther. 2017 Nov;16(11):2598-2608. (PMID: 28835386)
Oncotarget. 2017 Aug 23;8(60):102263-102276. (PMID: 29254242)
Lancet Oncol. 2015 Mar;16(3):257-65. (PMID: 25704439)
Oncotarget. 2018 Sep 7;9(70):33337-33347. (PMID: 30279964)
Clin Cancer Res. 2012 Feb 15;18(4):969-80. (PMID: 22223527)
Nat Methods. 2017 Sep;14(9):873-876. (PMID: 28783155)
N Engl J Med. 2016 Sep 1;375(9):819-29. (PMID: 27433843)
Science. 2017 Jul 28;357(6349):409-413. (PMID: 28596308)
Cell Rep. 2017 Aug 22;20(8):1818-1829. (PMID: 28834746)
J Clin Oncol. 2018 Jun 10;36(17):1675-1684. (PMID: 29570421)
المشرفين على المادة: 0 (B7-H1 Antigen)
0 (Immune Checkpoint Inhibitors)
0 (Immunosuppressive Agents)
تواريخ الأحداث: Date Created: 20230824 Date Completed: 20230828 Latest Revision: 20231119
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10449840
DOI: 10.1038/s41467-023-40745-5
PMID: 37620318
قاعدة البيانات: MEDLINE
الوصف
تدمد:2041-1723
DOI:10.1038/s41467-023-40745-5